nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2010 | Original Article

Biodistribution and radiation dosimetry of a positron emission tomographic ligand, ¹⁸F-SP203, to image metabotropic glutamate subtype 5 receptors in humans

verfasst von: Yasuyuki Kimura, Fabrice G. Siméon, Jun Hatazawa, P. David Mozley, Victor W. Pike, Robert B. Innis, Masahiro Fujita

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A new PET ligand, 3-fluoro-5-(2-(2-¹⁸F-(fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile (¹⁸F-SP203), is a positron emission tomographic radioligand selective for metabotropic glutamate subtype 5 receptors. The purposes of this study were to estimate the radiation-absorbed doses of ¹⁸F-SP203 in humans and to determine from the distribution of radioactivity in bone structures with various proportions of bone and red marrow whether ¹⁸F-SP203 undergoes defluorination.

Methods

Whole-body images were acquired for 5 h after injecting ¹⁸F-SP203 in seven healthy humans. Urine was collected at various time points. Radiation-absorbed doses were estimated by the Medical Internal Radiation Dose scheme.

Results

After injecting ¹⁸F-SP203, the two organs with highest radiation exposure were urinary bladder wall and gallbladder wall, consistent with both urinary and fecal excretion. In the skeleton, most of the radioactivity was in bone structures that contain red marrow and not in those without red marrow. Although the dose to red marrow (30.9 μSv/MBq) was unusually high, the effective dose (17.8 μSv/MBq) of ¹⁸F-SP203 was typical of that of other ¹⁸F radiotracers.

Conclusion

¹⁸F-SP203 causes an effective dose in humans typical of several other ¹⁸F radioligands and undergoes little defluorination.

Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 2004;25:265–72.CrossRefPubMed

Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with ¹¹C-ABP688. J Nucl Med 2007;48:247–52.PubMed

Brown AK, Kimura Y, Zoghbi SS, Siméon FG, Liow JS, Kreisl WC, et al. Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med 2008;49:2042–8.CrossRefPubMed

Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, et al. Radiosynthesis and preclinical evaluation of ¹¹C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006;47:698–705.PubMed

Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005;56:205–16.CrossRefPubMed

Siméon FG, Brown AK, Zoghbi SS, Patterson VM, Innis RB, Pike VW. Synthesis and simple ¹⁸F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. J Med Chem 2007;50:3256–66.CrossRefPubMed

Sprague DR, Chin FT, Liow JS, Fujita M, Burns HD, Hargreaves R, et al. Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [¹⁸F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J Nucl Med 2007;48:100–7.PubMed

Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981;26:389–400.CrossRefPubMed

The International Commission on Radiological Protection. Basic anatomical and physiological data: the skeleton. ICRP Publication 70. Ann ICRP 1995;25:1–80.

10.

The International Commission on Radiological Protection. Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89. Ann ICRP. 2002;32:1–277.

11.

Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys 1973;25:147–61.CrossRefPubMed

12.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed

13.

Code of Federal Regulations. Title 21: Food and Drugs. Chapter 1 – Food and Drug Administration, Department of Health and Human Services. Part 361 – Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research. Sect. 361.1: Radioactive drugs for certain research uses; 2010

14.

International Commission on Radiological Protection. Radiological protection in biomedical research. ICRP Publication 62. Ann ICRP 1993;22:A1.

15.

Ryu YH, Liow JS, Zoghbi S, Fujita M, Collins J, Tipre D, et al. Disulfiram inhibits defluorination of ¹⁸F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT_1A receptors in human brain. J Nucl Med 2007;48:1154–61.CrossRefPubMed

16.

Shetty HU, Zoghbi SS, Simeon FG, Liow JS, Brown AK, Kannan P, et al. Radiodefluorination of 3-fluoro-5-(2-(2-[¹⁸F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([¹⁸F]SP203), a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain. J Pharmacol Exp Ther 2008;327:727–35.CrossRefPubMed

17.

Bogaards JJ, Venekamp JC, Salmon FG, van Bladeren PJ. Conjugation of isoprene monoepoxides with glutathione, catalyzed by α, μ, π and θ-class glutathione S-transferases of rat and man. Chem Biol Interact 1999;117:1–14.CrossRefPubMed

18.

Cannady EA, Chien C, Jones TM, Borel AG. In vitro metabolism of the epoxide substructure of cryptophycins by cytosolic glutathione S-transferase: species differences and stereoselectivity. Xenobiotica 2006;36:659–70.CrossRefPubMed

19.

Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. ¹⁸F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003;44:1482–8.PubMed

20.

Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, et al. PET-based radiation dosimetry in man of ¹⁸F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004;45:1966–71.PubMed

21.

Deterding TA, Votaw JR, Wang CK, Eshima D, Eshima L, Keil R, et al. Biodistribution and radiation dosimetry of the dopamine transporter ligand [¹⁸F]FECNT. J Nucl Med 2001;42:376–81.PubMed

22.

Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of ¹⁸F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50:818–22.CrossRefPubMed

23.

Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2-[¹⁸F]fluoro-A-85380 in human PET imaging studies. Nucl Med Biol 2005;32:869–74.CrossRefPubMed

24.

Brown WD, Oakes TR, DeJesus OT, Taylor MD, Roberts AD, Nickles RJ, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med 1998;39:1884–91.PubMed

25.

Robeson W, Dhawan V, Belakhlef A, Ma Y, Pillai V, Chaly T, et al. Dosimetry of the dopamine transporter radioligand ¹⁸F-FPCIT in human subjects. J Nucl Med 2003;44:961–6.PubMed

26.

Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998;25:565–74.CrossRefPubMed

Titel: Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18F-SP203, to image metabotropic glutamate subtype 5 receptors in humans
verfasst von: Yasuyuki Kimura
Fabrice G. Siméon
Jun Hatazawa
P. David Mozley
Victor W. Pike
Robert B. Innis
Masahiro Fujita
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1447-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

FDG-PET/CT in infections: the imaging method of choice?

Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer

The options for the future production of the medical isotope 99Mo

Before and after treatment 18F-FDG PET/CT images in a patient with cutaneous T-cell lymphoma

Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters